Eagle Pharmaceuticals | Sustainability Performance
Develops injectable and specialty pharmaceutical products.
2007
United States
51 - 200 employees
Pharmaceuticals
$100M - 500M in revenue
Sustainability Ranking & Industry Benchmark
#11458
Overall#2574
in United States#270
in PharmaceuticalsSustainability Maturity
Sustainability Intent
Overview
Governance
TargetsESG scores and ExclusionsFinancial Data
Business performanceCapital & innovationAnalyst projections
Market cap
Revenue
R&D intensity
Controversy level
- Eagle Pharmaceuticals faced FDA Form 483 observations and quality compliance scrutiny over injectable products, plus periodic generic drug pricing practices affecting hospital customers.
Market cap
Revenue
EBITDA
Operating margin
Revenue & EBITDA
$316.0MFY2022 revenue
Total Annual
Revenue & EBITDA
($ B)
Annual revenue
EBITDA
3 year change
Margin trends
Margin as % of revenue
Gross margin
Operating margin
Net margin
Powered by illuminem
Free cashflow
Capex
Debt/equity ratio
R&D intensity
10.8%FY2022
R&D as % of revenue
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Return on invested capital
12.0%FY2026
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Analyst revenue estimates & actuals
Analyst consensus vs actuals
($ B)
Actual revenue
Consensus estimates
Estimate only
0.2
▼ 4.0%
0.2
▼ 7.3%
0.3
▼ 3.2%
0.3
2027Powered by illuminem
Environmental policy coverage
Carbon reduction policy
Not available
Human rights policy
Not available
Recycling policy
Not available
Workplace health & safety policy
Not available
57%
Independent Directors
4 out of 7 incl. management
Overall score
18
Environment
3
Social
22
Governance
30
Exclusion screening
Adult content
Not available
Alcoholic
Not available
Animal testing
Available
Firearms
Not available
Tobacco
Not available
Gambling
Not available
Nuclear
Not available
